Dogan Vatansever
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dogan Vatansever has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Cagatay Taskiran
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Koc University School of Medicine
13 shared publications - Burak Giray
Koc University
9 shared publications Burak Giray
Koç University School of Medicine Istanbul Turkey
5 shared publicationsMacit Arvas
Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey
5 shared publicationsCagatay Taskiran
Koç University School of Medicine Istanbul Turkey
4 shared publications- Salih Taşkın
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
4 shared publications
Latest Publications
- 30 September 2026
- Published by Cetus Publishing in Türk Jinekolojik Onkoloji Dergisi
- Vol. 26 (2) , 72-79
Mini-laparoscopic Surgical Staging in Locally Advanced Cervical Cancer
Background: To evaluate the feasibility, safety, and surgical outcomes of mini-laparoscopic para-aortic lymph node (PALN) dissection—with or without simultaneous ovarian transposition—in patients with locally advanced cervical cancer prior to chemoradiotherapy. Methods: This retrospective study evaluated nine patients with FIGO 2009 stage IB2–IVA cervical cancer who underwent mini laparoscopic PALN assessment using a 5-mm optical transumbilical trocar and 3.5-mm/5-mm ancillary trocars at a tertiary university hospital. Premenopausal patients underwent concurrent bilateral salpingectomy and lateral ovarian transposition. Demographic characteristics, operative times, intraoperative/postoperative complications, node yields, length of hospital stay, and time to chemoradiotherapy were recorded and analyzed. Results: The mean patient age was 41.25±9.50 years, and the mean body mass index (BMI) was 24.5±3.24〖" kg/m" 〗^2. Five premenopausal patients successfully underwent mini-laparoscopic PALN dissection combined with ovarian transposition. The mean operative time was 205±51.4 minutes, and the mean number of removed para-aortic lymph nodes was 15.89±7.61. One intraoperative external iliac vein injury occurred, which was successfully repaired intraoperatively with primary suture, followed by postoperatively managed chylous ascites. The mean hospital stay was 5±3.02 days. All nine patients successfully initiated definitive chemoradiotherapy within 20 days of surgery. Conclusion: Mini-laparoscopic PALN dissection is a technically feasible and safe procedure for staging locally advanced cervical cancer, offering adequate node yield and potential for rapid postoperative recovery without delaying primary chemoradiotherapy. Larger prospective controlled studies are warranted to confirm these findings and establish long-term clinical outcomes.
- 30 September 2026
- Published by Cetus Publishing in Türk Jinekolojik Onkoloji Dergisi
- Vol. 26 (2) , 72-79
Mini-laparoscopic Surgical Staging in Locally Advanced Cervical Cancer
Background: To evaluate the feasibility, safety, and surgical outcomes of mini-laparoscopic para-aortic lymph node (PALN) dissection—with or without simultaneous ovarian transposition—in patients with locally advanced cervical cancer prior to chemoradiotherapy. Methods: This retrospective study evaluated nine patients with FIGO 2009 stage IB2–IVA cervical cancer who underwent mini laparoscopic PALN assessment using a 5-mm optical transumbilical trocar and 3.5-mm/5-mm ancillary trocars at a tertiary university hospital. Premenopausal patients underwent concurrent bilateral salpingectomy and lateral ovarian transposition. Demographic characteristics, operative times, intraoperative/postoperative complications, node yields, length of hospital stay, and time to chemoradiotherapy were recorded and analyzed. Results: The mean patient age was 41.25±9.50 years, and the mean body mass index (BMI) was 24.5±3.24〖" kg/m" 〗^2. Five premenopausal patients successfully underwent mini-laparoscopic PALN dissection combined with ovarian transposition. The mean operative time was 205±51.4 minutes, and the mean number of removed para-aortic lymph nodes was 15.89±7.61. One intraoperative external iliac vein injury occurred, which was successfully repaired intraoperatively with primary suture, followed by postoperatively managed chylous ascites. The mean hospital stay was 5±3.02 days. All nine patients successfully initiated definitive chemoradiotherapy within 20 days of surgery. Conclusion: Mini-laparoscopic PALN dissection is a technically feasible and safe procedure for staging locally advanced cervical cancer, offering adequate node yield and potential for rapid postoperative recovery without delaying primary chemoradiotherapy. Larger prospective controlled studies are warranted to confirm these findings and establish long-term clinical outcomes.
- Open Access
Predicting the Unpredictable: Development and External Validation of the GO SOAR Surgical Risk Calculator for Data-Driven Predictions of Surgical Complications in Gynaecological Oncology Surgery
Background/Objectives: Universal surgical risk calculators are not validated for use and poorly predict postoperative morbidity and mortality for women undergoing gynaecological oncology surgery. This adversely affects communication of risk resulting in poorly informed decisions and missed opportunities for medical optimization to mitigate risk preoperatively. We present the development and external validation of our novel GO SOAR surgical risk calculator for use to preoperatively predict postoperative thirty-day surgical morbidity and mortality in relation to gynaecological oncology surgeries. Methods: New logistic regression models were developed using the GO SOAR1 training cohort (n = 1811) and externally validated in an independent prospective cohort (n = 416) for two outcomes: thirty-day postoperative mortality (alive versus dead) and thirty-day postoperative morbidity (any complication (Clavien–Dindo I–V) versus none). Performance of the GO SOAR models was compared against established all-purpose surgical risk calculators (SORT/POSSUM/P-POSSUM/NSQIP). Model discrimination was assessed with sensitivity calculated at a clinically significant prespecified specificity threshold of 90%. Results: For mortality, AUROC was 0.752 (95% CI 0.570–0.935) for GO SOAR full and 0.795 (95% CI 0.660–0.930) for GO SOAR condensed; corresponding sensitivities at 90% specificity were 57.1% and 42.9%. For morbidity, AUROC was 0.698 (95% CI 0.641–0.755) and 0.703 (95% CI 0.646–0.760) for the full and condensed models, respectively, with sensitivities of 30.4% and 32.1% at 90% specificity. Conclusions: The GO SOAR model using a data-driven, gynaecological-oncology-specific approach at 90% specificity, achieved the highest observed sensitivity among the evaluated calculators. Accurate surgical risk predictions are crucial for major oncological surgery, where complications can diminish quality of life and affect long-term cancer survival. A model such as the GO SOAR surgical risk calculator that uses readily available preoperative data, regardless of income setting, is essential in reducing global disparities in surgical outcomes.
Open AccessPredicting the Unpredictable: Development and External Validation of the GO SOAR Surgical Risk Calculator for Data-Driven Predictions of Surgical Complications in Gynaecological Oncology Surgery
Background/Objectives: Universal surgical risk calculators are not validated for use and poorly predict postoperative morbidity and mortality for women undergoing gynaecological oncology surgery. This adversely affects communication of risk resulting in poorly informed decisions and missed opportunities for medical optimization to mitigate risk preoperatively. We present the development and external validation of our novel GO SOAR surgical risk calculator for use to preoperatively predict postoperative thirty-day surgical morbidity and mortality in relation to gynaecological oncology surgeries. Methods: New logistic regression models were developed using the GO SOAR1 training cohort (n = 1811) and externally validated in an independent prospective cohort (n = 416) for two outcomes: thirty-day postoperative mortality (alive versus dead) and thirty-day postoperative morbidity (any complication (Clavien–Dindo I–V) versus none). Performance of the GO SOAR models was compared against established all-purpose surgical risk calculators (SORT/POSSUM/P-POSSUM/NSQIP). Model discrimination was assessed with sensitivity calculated at a clinically significant prespecified specificity threshold of 90%. Results: For mortality, AUROC was 0.752 (95% CI 0.570–0.935) for GO SOAR full and 0.795 (95% CI 0.660–0.930) for GO SOAR condensed; corresponding sensitivities at 90% specificity were 57.1% and 42.9%. For morbidity, AUROC was 0.698 (95% CI 0.641–0.755) and 0.703 (95% CI 0.646–0.760) for the full and condensed models, respectively, with sensitivities of 30.4% and 32.1% at 90% specificity. Conclusions: The GO SOAR model using a data-driven, gynaecological-oncology-specific approach at 90% specificity, achieved the highest observed sensitivity among the evaluated calculators. Accurate surgical risk predictions are crucial for major oncological surgery, where complications can diminish quality of life and affect long-term cancer survival. A model such as the GO SOAR surgical risk calculator that uses readily available preoperative data, regardless of income setting, is essential in reducing global disparities in surgical outcomes.
- Open Access
- 16 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6326
Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer
Background/Objectives: The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system redefines endometrial cancer staging by integrating histopathological and molecular parameters into conventional anatomic assessment. We aimed to quantify stage migration following reclassification from FIGO 2009 to FIGO 2023, to evaluate its impact on survival, and to identify independent prognostic determinants within this restaged cohort. Methods: In this two-center retrospective cohort study, 291 patients with histologically confirmed endometrial cancer were restaged according to both FIGO 2009 and FIGO 2023 systems. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and independent prognostic determinants were identified through multivariable Cox proportional hazards modeling. Results: Application of FIGO 2023 resulted in stage migration in 32.0% of patients, with 30.6% upstaged and 1.4% downstaged. Upstaged patients demonstrated significantly worse PFS and OS compared with downstaged patients and patients without stage change (p < 0.001 for both). Notably, among patients initially classified as FIGO 2009 stage I, 38% were reassigned to a higher stage and exhibited a marked survival disadvantage (p < 0.001). In multivariable analysis, advanced age and positive surgical margins independently predicted both poorer PFS and OS, while lymphovascular space invasion (LVSI) independently predicted inferior PFS. The association with positive surgical margins, however, likely reflected concurrent advanced-stage disease. Conclusions: The FIGO 2023 staging system results in substantial stage redistribution in endometrial cancer and provides clearer survival discrimination, particularly by identifying previously unrecognized high-risk subgroups within early-stage disease. The significant survival disadvantage observed among upstaged patients indicates that the revised system may more accurately reflect biologically driven risk stratification. However, stage migration was not independently associated with survival after adjustment for its constituent pathological factors.
- 16 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6326
Open AccessPrognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer
Background/Objectives: The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system redefines endometrial cancer staging by integrating histopathological and molecular parameters into conventional anatomic assessment. We aimed to quantify stage migration following reclassification from FIGO 2009 to FIGO 2023, to evaluate its impact on survival, and to identify independent prognostic determinants within this restaged cohort. Methods: In this two-center retrospective cohort study, 291 patients with histologically confirmed endometrial cancer were restaged according to both FIGO 2009 and FIGO 2023 systems. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and independent prognostic determinants were identified through multivariable Cox proportional hazards modeling. Results: Application of FIGO 2023 resulted in stage migration in 32.0% of patients, with 30.6% upstaged and 1.4% downstaged. Upstaged patients demonstrated significantly worse PFS and OS compared with downstaged patients and patients without stage change (p < 0.001 for both). Notably, among patients initially classified as FIGO 2009 stage I, 38% were reassigned to a higher stage and exhibited a marked survival disadvantage (p < 0.001). In multivariable analysis, advanced age and positive surgical margins independently predicted both poorer PFS and OS, while lymphovascular space invasion (LVSI) independently predicted inferior PFS. The association with positive surgical margins, however, likely reflected concurrent advanced-stage disease. Conclusions: The FIGO 2023 staging system results in substantial stage redistribution in endometrial cancer and provides clearer survival discrimination, particularly by identifying previously unrecognized high-risk subgroups within early-stage disease. The significant survival disadvantage observed among upstaged patients indicates that the revised system may more accurately reflect biologically driven risk stratification. However, stage migration was not independently associated with survival after adjustment for its constituent pathological factors.
- Open Access
- 29 July 2026
- Published by Wiley in Biotechnology Journal
- Vol. 21 (7) , e70287
Benchmarking Ultra‐Low Attachment and Photopatterned GelMA 3D Culture Platforms for Modeling Cancer Stemness in High‐Grade Serous Ovarian Cancer
High‐grade serous ovarian cancer (HGSOC) exhibits pronounced intratumoral heterogeneity and chemoresistance, demanding experimental platforms that more accurately recapitulate stemness‐driven relapse. Despite increasing use of three‐dimensional (3D) systems in cancer research, their comparative translational performance in ovarian cancer remains unclear. Here, we systematically benchmark two scalable 3D platforms, scaffold‐free ultra‐low attachment (ULA) spheroids and extracellular matrix mimetic photopatterned gelatin methacryloyl (GelMA) hydrogels, using HGSOC cell lines and patient‐derived primary samples. Under matched conditions, both systems enhanced cancer stem cell (CSC) associated phenotypes relative to 2D culture, including induction of stemness markers, CSC surface populations, epithelial to mesenchymal transition signatures, and drug resistance. ULA enabled long‐term spheroid maturation and robust expansion of intrinsically stem‐like populations, whereas GelMA photopatterning provided spatially defined microenvironmental control that promoted rapid and uniform spheroid formation and efficiently induced stem‐like traits in low‐stemness models. Notably, baseline SOX2 expression partially correlated with chemoresistance, supporting the biological relevance of CSC enriched platforms. Collectively, this platform level comparison establishes complementary, biotechnology driven strategies for reproducible modeling of HGSOC stemness and therapy resistance, with implications for translational drug evaluation and precision oncology.
- 29 July 2026
- Published by Wiley in Biotechnology Journal
- Vol. 21 (7) , e70287
Open AccessBenchmarking Ultra‐Low Attachment and Photopatterned GelMA 3D Culture Platforms for Modeling Cancer Stemness in High‐Grade Serous Ovarian Cancer
High‐grade serous ovarian cancer (HGSOC) exhibits pronounced intratumoral heterogeneity and chemoresistance, demanding experimental platforms that more accurately recapitulate stemness‐driven relapse. Despite increasing use of three‐dimensional (3D) systems in cancer research, their comparative translational performance in ovarian cancer remains unclear. Here, we systematically benchmark two scalable 3D platforms, scaffold‐free ultra‐low attachment (ULA) spheroids and extracellular matrix mimetic photopatterned gelatin methacryloyl (GelMA) hydrogels, using HGSOC cell lines and patient‐derived primary samples. Under matched conditions, both systems enhanced cancer stem cell (CSC) associated phenotypes relative to 2D culture, including induction of stemness markers, CSC surface populations, epithelial to mesenchymal transition signatures, and drug resistance. ULA enabled long‐term spheroid maturation and robust expansion of intrinsically stem‐like populations, whereas GelMA photopatterning provided spatially defined microenvironmental control that promoted rapid and uniform spheroid formation and efficiently induced stem‐like traits in low‐stemness models. Notably, baseline SOX2 expression partially correlated with chemoresistance, supporting the biological relevance of CSC enriched platforms. Collectively, this platform level comparison establishes complementary, biotechnology driven strategies for reproducible modeling of HGSOC stemness and therapy resistance, with implications for translational drug evaluation and precision oncology.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (2)
Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)
Bese T, et al. J Gynecol Oncol. 2025 Oct;37:e23. https://doi.org/10.3802/jgo.2026.37.e23
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (2)
Open AccessComparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)
Bese T, et al. J Gynecol Oncol. 2025 Oct;37:e23. https://doi.org/10.3802/jgo.2026.37.e23
- 31 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (6) , 101803
Fertility-sparing treatment in ovarian clear cell carcinoma with concomitant seromucinous borderline ovarian tumor
- 31 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (6) , 101803
Fertility-sparing treatment in ovarian clear cell carcinoma with concomitant seromucinous borderline ovarian tumor
- Open Access
- 4 November 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (11) , 1813-1819
Non-invasive mediastinal lymph node metastasis of serous borderline ovarian tumor
The patient was advised to undergo a laparotomy for the evaluation of the pelvic masses, with intra-operative frozen section analysis. It was explained that if intra-operative pathology evaluation indicated malignancy, a staging surgery would be performed. In the case of a borderline ovarian tumor, a fertility-sparing approach may be considered following a comprehensive assessment of the entire abdomen. The patient then underwent bilateral ovarian cystectomy, and intra-operative frozen sections of the ovarian cysts were reported as borderline ovarian tumors. Additionally, multiple implants over the pouch of Douglas peritoneum and the mesentery of the sigmoid colon were confirmed to be borderline ovarian tumor implants. The patient subsequently underwent omentectomy, appendectomy, and pelvic and para-aortic lymphadenectomy up to the renal vein due to suspicious lymph nodes observed on pre-operative imaging. The estimated operation time and blood loss were 180 min and 200 mL, respectively. There were no post-operative complications, and she was discharged on post-operative day 4.
- 4 November 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (11) , 1813-1819
Open AccessNon-invasive mediastinal lymph node metastasis of serous borderline ovarian tumor
The patient was advised to undergo a laparotomy for the evaluation of the pelvic masses, with intra-operative frozen section analysis. It was explained that if intra-operative pathology evaluation indicated malignancy, a staging surgery would be performed. In the case of a borderline ovarian tumor, a fertility-sparing approach may be considered following a comprehensive assessment of the entire abdomen. The patient then underwent bilateral ovarian cystectomy, and intra-operative frozen sections of the ovarian cysts were reported as borderline ovarian tumors. Additionally, multiple implants over the pouch of Douglas peritoneum and the mesentery of the sigmoid colon were confirmed to be borderline ovarian tumor implants. The patient subsequently underwent omentectomy, appendectomy, and pelvic and para-aortic lymphadenectomy up to the renal vein due to suspicious lymph nodes observed on pre-operative imaging. The estimated operation time and blood loss were 180 min and 200 mL, respectively. There were no post-operative complications, and she was discharged on post-operative day 4.
- Open Access
- 28 December 2023
- Published by Cetus Publishing in Türk Jinekolojik Onkoloji Dergisi
- Vol. 23 (3) , 52-57
The clinical and reproductive outcomes of endometrial intraepithelial neoplasia: experience of 117 cases
Aim: Hysterectomy is the suggested treatment for endometrial intraepithelial neoplasia since there is a high risk of coexisting endometrial adenocarcinoma in this subset of patients. However, fertility sparing treatment modalities can also be an option for patients with endometrial intraepithelial neoplasia who desire to preserve their fertility. In this study our aim was to evaluate the clinical and reproductive outcomes of endometrial intraepithelial neoplasia. Materials and methods: We retrospectively analyzed the records of 117 patients with atypical hyperplasia (AH)/endometrial intraepithelial neoplasia (EIN) in a tertiary gynecological cancer center. The median follow-up time was 54 (7-96) months. Results: One hundred and one women underwent hysterectomy. The rate of coexistent endometrial carcinoma in women with AH/EIN was 33.7%. Sixteen women were treated conservatively. The complete response rate was 75% in patients after a treatment period of 12 months. Four of the patients in the infertile group had a successful live birth, 2 spontaneously and 2 with in vitro fertilization. Two patients in the fertile group had a successful live birth, 2 spontaneously. Conclusion: Fertility sparing management is a feasible option for patients with atypical hyperplasia. However, it is crucial that there are high rates of coexisting endometrial cancer in these patients. Patients with AH/EIN should be followed up carefully for endometrial adenocarcinoma with regular endometrial samplings.
- 28 December 2023
- Published by Cetus Publishing in Türk Jinekolojik Onkoloji Dergisi
- Vol. 23 (3) , 52-57
Open AccessThe clinical and reproductive outcomes of endometrial intraepithelial neoplasia: experience of 117 cases
Aim: Hysterectomy is the suggested treatment for endometrial intraepithelial neoplasia since there is a high risk of coexisting endometrial adenocarcinoma in this subset of patients. However, fertility sparing treatment modalities can also be an option for patients with endometrial intraepithelial neoplasia who desire to preserve their fertility. In this study our aim was to evaluate the clinical and reproductive outcomes of endometrial intraepithelial neoplasia. Materials and methods: We retrospectively analyzed the records of 117 patients with atypical hyperplasia (AH)/endometrial intraepithelial neoplasia (EIN) in a tertiary gynecological cancer center. The median follow-up time was 54 (7-96) months. Results: One hundred and one women underwent hysterectomy. The rate of coexistent endometrial carcinoma in women with AH/EIN was 33.7%. Sixteen women were treated conservatively. The complete response rate was 75% in patients after a treatment period of 12 months. Four of the patients in the infertile group had a successful live birth, 2 spontaneously and 2 with in vitro fertilization. Two patients in the fertile group had a successful live birth, 2 spontaneously. Conclusion: Fertility sparing management is a feasible option for patients with atypical hyperplasia. However, it is crucial that there are high rates of coexisting endometrial cancer in these patients. Patients with AH/EIN should be followed up carefully for endometrial adenocarcinoma with regular endometrial samplings.
- 11 November 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (1) , 113-124
IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients
Are the IVF parameters and the steroidogenic luteal characteristics of random-start IVF cycles different from conventional cycles in cancer patients? No; controlled ovarian stimulation cycles randomly started at late follicular phase (LFP) and luteal phase (LP) are totally comparable to those conventional IVF cycles started at early follicular phase (EFP) in terms of the expression of the enzymes involved in cholesterol utilization and steroid hormone biosynthesis pathways, gonadotropin receptor expression and, estradiol (E2) and progesterone (P4) production in addition to the similarities in ovarian response to gonadotropin stimulation, oocyte yield, fertilization rate and embryo development competency in cancer patients. Random start ovarian stimulation protocols are commonly employed for oocyte and embryo freezing for fertility preservation in cancer patients with time constraints who do not have sufficient time to undergo ovarian stimulation initiated conventionally at EFP of the next cycle. No data is available regarding the molecular steroidogenic features of these cycles analyzed together with the clinical IVF characteristics in cancer patients. We aimed to address this question in this study to help understand how similar the random start cycles are to the conventional start ones. A clinical translational research study conducted in 62 cancer patients undergoing IVF for fertility preservation between the years 2017 and 2022. Sixty-two patients who were diagnosed with different types of cancer and underwent ovarian stimulation for oocyte (n = 41) and embryo (n = 21) cryopreservation using GnRH antagonist protocol and human menopausal gonadotropins before receiving cancer treatment/surgery were enrolled in the study. For patients with breast cancer and endometrial cancer the aromatase inhibitor letrozole was used with gonadotropin stimulation. Ovarian stimulation was initiated conventionally at EFP in 22 patients and served as control while it was started at LFP in 20, and mid-LP in the other 20 patients. The luteinized granulosa cells (GCs) were recovered from follicular aspirates during oocyte retrieval procedure and used for the experiments separately for each individual patient. The expression of the enzymes involved in sex steroid biosynthesis (StAR, 3β-HSD, Aromatase) and cholesterol synthesis (3-hydroxy 3-methylglutaryl Co-A reductase (HMG-Co-A reductase)), utilization (hormone sensitive lipase (HSL)), and storage (Acetyl-Coenzyme A acetyltransferase 1 (ACAT-1)), and gonadotropin receptor expression status were analyzed using immunoblotting and RT-PCR methods. Laser confocal immunofluorescence imaging was applied to analyze and compare the expression patterns of the steroidogenic enzymes and their relation with mitochondria. In vitro E2 and P4 production by the cells were compared among the groups. Baseline demographic and IVF characteristics of the patients undergoing the conventional start and random start IVF cycles were similar. Duration of gonadotropin stimulation was significantly longer in LFP and LP start cycles in comparison to the conventional ones. Ovarian response to gonadotropin stimulation, mature and total oocyte yield, fertilization and Day 5 blastulation rates of the embryos were comparable between the conventional versus random start cycles. When the luteal GCs of these random start cycles were analyzed we could not find any gross differences between these cycles in terms of the viability index and gross light microscopic morphologic features. More detailed analysis of the molecular luteal characteristics of the cells using RT-PCR, immunoblotting methods revealed that the expression profiles of the gonadotropin receptors, and the enzymes involved in sex steroid biosynthesis and cholesterol synthesis/utilization, and the steroidogenic activity of the luteal GCs of the random start cycles are almost identical to those of the conventional start cycles. Confocal image analysis demonstrated similar patterns in the signal expression profiles of the steroidogenic enzymes and their co-localization within mitochondria. N/A. Caution should be exercised when interpreting our data and counseling cancer patients seeking fertility preservation because it is still unclear if previous exposure to cancer drugs, different ovarian pathologies or infertility etiologies, previous ovarian surgery and/or any other underlying diseases that are concomitantly present with cancer may cause a difference between conventional and random start stimulation protocols in terms of IVF parameters, luteal function and reproductive outcome. Relatively low number of patients in each stimulation protocol and pooling of luteal GCs for each patient rather than individual analysis of each follicle and oocyte are additional limitations of our study. Our findings provide reassurance that random start protocol offers cancer patients an equally good prospect of fertility preservation as conventional IVF. Funded by the School of Medicine, the Graduate School of Health Sciences of Koc University and Koç University Research Center for Translational Medicine (KUTTAM), equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. All authors declare no conflict of interest. N/A.
- 11 November 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (1) , 113-124
IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients
Are the IVF parameters and the steroidogenic luteal characteristics of random-start IVF cycles different from conventional cycles in cancer patients? No; controlled ovarian stimulation cycles randomly started at late follicular phase (LFP) and luteal phase (LP) are totally comparable to those conventional IVF cycles started at early follicular phase (EFP) in terms of the expression of the enzymes involved in cholesterol utilization and steroid hormone biosynthesis pathways, gonadotropin receptor expression and, estradiol (E2) and progesterone (P4) production in addition to the similarities in ovarian response to gonadotropin stimulation, oocyte yield, fertilization rate and embryo development competency in cancer patients. Random start ovarian stimulation protocols are commonly employed for oocyte and embryo freezing for fertility preservation in cancer patients with time constraints who do not have sufficient time to undergo ovarian stimulation initiated conventionally at EFP of the next cycle. No data is available regarding the molecular steroidogenic features of these cycles analyzed together with the clinical IVF characteristics in cancer patients. We aimed to address this question in this study to help understand how similar the random start cycles are to the conventional start ones. A clinical translational research study conducted in 62 cancer patients undergoing IVF for fertility preservation between the years 2017 and 2022. Sixty-two patients who were diagnosed with different types of cancer and underwent ovarian stimulation for oocyte (n = 41) and embryo (n = 21) cryopreservation using GnRH antagonist protocol and human menopausal gonadotropins before receiving cancer treatment/surgery were enrolled in the study. For patients with breast cancer and endometrial cancer the aromatase inhibitor letrozole was used with gonadotropin stimulation. Ovarian stimulation was initiated conventionally at EFP in 22 patients and served as control while it was started at LFP in 20, and mid-LP in the other 20 patients. The luteinized granulosa cells (GCs) were recovered from follicular aspirates during oocyte retrieval procedure and used for the experiments separately for each individual patient. The expression of the enzymes involved in sex steroid biosynthesis (StAR, 3β-HSD, Aromatase) and cholesterol synthesis (3-hydroxy 3-methylglutaryl Co-A reductase (HMG-Co-A reductase)), utilization (hormone sensitive lipase (HSL)), and storage (Acetyl-Coenzyme A acetyltransferase 1 (ACAT-1)), and gonadotropin receptor expression status were analyzed using immunoblotting and RT-PCR methods. Laser confocal immunofluorescence imaging was applied to analyze and compare the expression patterns of the steroidogenic enzymes and their relation with mitochondria. In vitro E2 and P4 production by the cells were compared among the groups. Baseline demographic and IVF characteristics of the patients undergoing the conventional start and random start IVF cycles were similar. Duration of gonadotropin stimulation was significantly longer in LFP and LP start cycles in comparison to the conventional ones. Ovarian response to gonadotropin stimulation, mature and total oocyte yield, fertilization and Day 5 blastulation rates of the embryos were comparable between the conventional versus random start cycles. When the luteal GCs of these random start cycles were analyzed we could not find any gross differences between these cycles in terms of the viability index and gross light microscopic morphologic features. More detailed analysis of the molecular luteal characteristics of the cells using RT-PCR, immunoblotting methods revealed that the expression profiles of the gonadotropin receptors, and the enzymes involved in sex steroid biosynthesis and cholesterol synthesis/utilization, and the steroidogenic activity of the luteal GCs of the random start cycles are almost identical to those of the conventional start cycles. Confocal image analysis demonstrated similar patterns in the signal expression profiles of the steroidogenic enzymes and their co-localization within mitochondria. N/A. Caution should be exercised when interpreting our data and counseling cancer patients seeking fertility preservation because it is still unclear if previous exposure to cancer drugs, different ovarian pathologies or infertility etiologies, previous ovarian surgery and/or any other underlying diseases that are concomitantly present with cancer may cause a difference between conventional and random start stimulation protocols in terms of IVF parameters, luteal function and reproductive outcome. Relatively low number of patients in each stimulation protocol and pooling of luteal GCs for each patient rather than individual analysis of each follicle and oocyte are additional limitations of our study. Our findings provide reassurance that random start protocol offers cancer patients an equally good prospect of fertility preservation as conventional IVF. Funded by the School of Medicine, the Graduate School of Health Sciences of Koc University and Koç University Research Center for Translational Medicine (KUTTAM), equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. All authors declare no conflict of interest. N/A.